Application of virus immunotherapy drug compound in preparation of drugs for treating HBV infection

A technology of immunotherapeutic drugs and antiviral drugs, applied in the field of biomedicine, can solve the problems of not being able to effectively improve the primary immune response, GM-CSF cannot provide adjuvant activity, etc., and achieve the prevention of re-infection, easy promotion, and convenient use Effect

Inactive Publication Date: 2020-03-06
FUDAN UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Hasan et al found that GM-CSF cannot provide significant adjuvant activity by intramuscularly injecting GM-CSF immediately before injecting recombinant hepatitis B vaccine to normal people, that is, it cannot effectively improve the primary immune response[3]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of virus immunotherapy drug compound in preparation of drugs for treating HBV infection
  • Application of virus immunotherapy drug compound in preparation of drugs for treating HBV infection
  • Application of virus immunotherapy drug compound in preparation of drugs for treating HBV infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0063] Example 1: The immunization strategy of GM-CSF combined with recombinant hepatitis B vaccine enhances the immune response of C57BL / 6 to recombinant hepatitis B subunit vaccine

[0064] Materials and Instruments:

[0065] Experimental materials: Genetic engineering (CHO) hepatitis B vaccine [Recombinant Hepatitis B Vaccine (CHO)], 10ug / 1.0mL, recombinant human granulocyte-macrophage colony-stimulating factor for injection [Recombinant Human Granulocyte / Macrophage Clolony-Stimulating Factor for Injection ], 300ug / support, CHO-expressed genetically engineered hepatitis B vaccine stock solution (HBsAg stock solution) was provided by North China Pharmaceutical Group Jintan Biotechnology Co., Ltd.

[0066] Main kits and instruments: RPMI 1640 culture medium (WISENT company); fetal bovine serum (Tianjin Haoyang Biological Products Co., Ltd.); mouse anti-rabbit IgG antibody: purchased from Sigma, HRP-labeled anti-mouse IgG, IgG1, IgG2a, purchased from at Southern Biotechnology...

Embodiment 2

[0133] Example 2: The immunization strategy of GM-CSF combined with recombinant hepatitis B vaccine breaks the immune tolerance of HBsAg transgenic mice and induces anti-HBsAg humoral immune response in transgenic mice

[0134] Materials and Instruments:

[0135] HBsAg transgenic mice (C57BL / 6J-Tg(AlblHBV)44Bri / Jf4J) were purchased from Shanghai Public Health Clinical Center affiliated to Fudan University. "Hepatitis B surface antigen enzyme-linked immunoassay diagnostic kit" and hepatitis B surface antigen standard were purchased from Beijing Jinhao Pharmaceutical Co., Ltd. Other experimental materials, main reagents and instruments are the same as in Example 1.

[0136] experiment method:

[0137] Animal grouping and immunization methods:

[0138] 35 HBsAg transgenic mice (C57BL / 6J-Tg(AlblHBV)44Bri / Jf4J) (initial serum HBsAg concentration is 5000-10000pg / ml), were randomly divided into 5 groups, 7 mice in each group, and the experimental grouping was performed according t...

Embodiment 3

[0161] Example 3: GM-CSF Combined with Recombinant Hepatitis B Vaccine Immune Strategy Breaks Immune Tolerance of HBsAg Transgenic Mice Induces Anti-HBsAg Cellular Immune Response in Transgenic Mice and Eliminates HBsAg in Liver

[0162] Materials and Instruments:

[0163] HBsAg transgenic mice (C57BL / 6J-Tg(AlblHBV)44Bri / Jf4J) were purchased from Shanghai Public Health Clinical Center affiliated to Fudan University. The primary antibody and secondary antibody of hepatitis B surface S antigen immunohistochemistry were purchased from Shanghai Changdao Biotechnology Co., Ltd. Other experimental materials, main reagents and instruments are the same as in Example 1.

[0164] Animal grouping and immunization methods:

[0165] Thirty-five HBsAg transgenic mice (C57BL / 6J-Tg(AlblHBV)44Bri / Jf4J) (initial serum HBsAg concentration was 5000-10000pg / ml) were randomly divided into 5 groups with 5 mice in each group. The experimental groups are shown in the table below. Each group of vacc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to view more

Abstract

The invention belongs to the field of biological medicines, and relates to a novel virus immunotherapy drug compound, in particular to an application of the virus immunotherapy medicine compound in preparation of a medicine for treating HBV infection, the virus immunotherapy medicine compound is composed of an antiviral medicine, an immunomodulatory medicine and a recombinant hepatitis B vaccine,virus replication is inhibited through the antiviral medicine, and then immunization is conducted in the mode of adding the immunomodulatory agent and the vaccine. An effective immune memory protection reaction is established for organisms, strong antibody protection and cellular immunity are generated, virus recurrence is prevented, a purpose of removing viruses is even achieved, and HBV reinfection is prevented. Compared with an existing antiviral immune medicine, the novel virus immunotherapy drug compound is safe and effective and can be used for clinically treating virus infection diseases.

Description

[0001] The present invention is a divisional application with the application number 201310322617.0, the application date is July 26, 2013, and the title of the invention is "a drug compound for virus immunotherapy and its use". technical field [0002] The invention belongs to the field of biomedicine and relates to a novel virus immunotherapy drug compound, in particular to the application of a virus immunotherapy drug compound in the preparation of drugs for treating HBV infection. Background technique [0003] The prior art discloses that hepatitis B is an infectious disease caused by hepatitis B virus (HBV), transmitted through blood and body fluids, and mainly based on liver damage. It is a serious public health problem, and the disease is harmful to human health. The threat is great. Studies have shown that after infection with hepatitis B, some patients will develop into a state of chronic persistent infection, which may evolve into liver cirrhosis or primary hepatoc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K38/19A61K38/21A61K31/7072A61K39/29A61K39/39A61P1/16A61P31/20
CPCA61K39/39A61K2039/545A61K2039/55522C12N2730/10134A61K38/193A61K38/21A61K31/513A61K31/522A61K31/675A61K31/7072A61K45/06A61K39/12A61K2300/00A61K47/60A61K39/292A61K38/212A61P1/16A61P31/20A61P37/04A61P43/00C12N7/00
Inventor 王宾王宪政张继明
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap